Literature DB >> 7666400

Diagnostic issues in a family with late onset type 2 neurofibromatosis.

D G Evans1, D Bourn, A Wallace, R T Ramsden, J D Mitchell, T Strachan.   

Abstract

We report a family with type 2 neurofibromatosis and late onset tumours. Five members of this family have developed hearing loss late in life, two of whom have only been shown to have the diagnosis in their seventies, and three other obligate gene carriers died undiagnosed at 64, 72, and 78 years of age. A missense mutation at the C-terminal end of the NF2 protein has been identified in this family and segregates with disease. The use of highly polymorphic markers for predictive testing is also shown. There appears to be an autosomal dominant form of spinocerebellar degeneration which is segregating separately to NF2 in this family, which created a diagnostic dilemma.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7666400      PMCID: PMC1050488          DOI: 10.1136/jmg.32.6.470

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  13 in total

1.  A second-generation linkage map of the human genome.

Authors:  J Weissenbach; G Gyapay; C Dib; A Vignal; J Morissette; P Millasseau; G Vaysseix; M Lathrop
Journal:  Nature       Date:  1992-10-29       Impact factor: 49.962

2.  Germline mutations in the neurofibromatosis type 2 tumour suppressor gene.

Authors:  D Bourn; S A Carter; S Mason; D Gareth; R Evans; T Strachan
Journal:  Hum Mol Genet       Date:  1994-05       Impact factor: 6.150

3.  A disease-associated germline deletion maps the type 2 neurofibromatosis (NF2) gene between the Ewing sarcoma region and the leukaemia inhibitory factor locus.

Authors:  C J Watson; L Gaunt; G Evans; K Patel; R Harris; T Strachan
Journal:  Hum Mol Genet       Date:  1993-06       Impact factor: 6.150

4.  DNA diagnosis of neurofibromatosis 2. Altered coding sequence of the merlin tumor suppressor in an extended pedigree.

Authors:  M MacCollin; T Mohney; J Trofatter; W Wertelecki; V Ramesh; J Gusella
Journal:  JAMA       Date:  1993-11-17       Impact factor: 56.272

5.  A genetic study of type 2 neurofibromatosis in the United Kingdom. II. Guidelines for genetic counselling.

Authors:  D G Evans; S M Huson; D Donnai; W Neary; V Blair; V Newton; T Strachan; R Harris
Journal:  J Med Genet       Date:  1992-12       Impact factor: 6.318

6.  A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor.

Authors:  J A Trofatter; M M MacCollin; J L Rutter; J R Murrell; M P Duyao; D M Parry; R Eldridge; N Kley; A G Menon; K Pulaski
Journal:  Cell       Date:  1993-03-12       Impact factor: 41.582

7.  Presymptomatic diagnosis for neurofibromatosis 2 with chromosome 22 markers.

Authors:  M H Ruttledge; S A Narod; J P Dumanski; D M Parry; R Eldridge; W Wertelecki; J Parboosingh; M C Faucher; G M Lenoir; V P Collins
Journal:  Neurology       Date:  1993-09       Impact factor: 9.910

8.  A clinical study of type 2 neurofibromatosis.

Authors:  D G Evans; S M Huson; D Donnai; W Neary; V Blair; V Newton; R Harris
Journal:  Q J Med       Date:  1992-08

9.  Neurofibromatosis type 2 appears to be a genetically homogeneous disease.

Authors:  S A Narod; D M Parry; J Parboosingh; G M Lenoir; M Ruttledge; G Fischer; R Eldridge; R L Martuza; M Frontali; J Haines
Journal:  Am J Hum Genet       Date:  1992-09       Impact factor: 11.025

10.  Central neurofibromatosis with bilateral acoustic neuroma: genetic, clinical and biochemical distinctions from peripheral neurofibromatosis.

Authors:  W R Kanter; R Eldridge; R Fabricant; J C Allen; T Koerber
Journal:  Neurology       Date:  1980-08       Impact factor: 9.910

View more
  9 in total

1.  Type II neurofibromatosis presenting as quadriceps atrophy.

Authors:  L Grazzi; L Chiapparini; E A Parati; S Giombini; D D'Amico; M Leone; G Bussone
Journal:  Ital J Neurol Sci       Date:  1998-04

Review 2.  Neurofibromatosis type 2.

Authors:  D G Evans; M Sainio; M E Baser
Journal:  J Med Genet       Date:  2000-12       Impact factor: 6.318

3.  Functional analysis of the neurofibromatosis type 2 protein by means of disease-causing point mutations.

Authors:  R P Stokowski; D R Cox
Journal:  Am J Hum Genet       Date:  2000-03       Impact factor: 11.025

4.  Germ-line mutations in the neurofibromatosis 2 gene: correlations with disease severity and retinal abnormalities.

Authors:  D M Parry; M M MacCollin; M I Kaiser-Kupfer; K Pulaski; H S Nicholson; M Bolesta; R Eldridge; J F Gusella
Journal:  Am J Hum Genet       Date:  1996-09       Impact factor: 11.025

5.  Misleading linkage results in an NF2 presymptomatic test owing to mosaicism.

Authors:  E K Bijlsma; A J Wallace; D G Evans
Journal:  J Med Genet       Date:  1997-11       Impact factor: 6.318

6.  Spinal and cutaneous schwannomatosis is a variant form of type 2 neurofibromatosis: a clinical and molecular study.

Authors:  D G Evans; S Mason; S M Huson; M Ponder; A E Harding; T Strachan
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-04       Impact factor: 10.154

7.  Origins of biallelic inactivation of NF2 in neurofibromatosis type 2.

Authors:  Lu Xue; Weiwei He; Yi Zhang; Zhigang Wang; Hongsai Chen; Zhe Chen; Weidong Zhu; Dongmei Liu; Huan Jia; Yi Jiang; Zhaoyan Wang; Hao Wu
Journal:  Neuro Oncol       Date:  2022-06-01       Impact factor: 13.029

8.  Genotype/phenotype correlations in type 2 neurofibromatosis (NF2): evidence for more severe disease associated with truncating mutations.

Authors:  D G Evans; L Trueman; A Wallace; S Collins; T Strachan
Journal:  J Med Genet       Date:  1998-06       Impact factor: 6.318

9.  A missense mutation in the NF2 gene results in moderate and mild clinical phenotypes of neurofibromatosis type 2.

Authors:  L Kluwe; V F Mautner
Journal:  Hum Genet       Date:  1996-02       Impact factor: 4.132

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.